Stressing on the efficacy of indigenous COVID-19 vaccines, the Indian Council of Medical Research (ICMR) on Thursday stated interim outcomes of the continued medical trials indicated that they might be effective against the mutated virus strains reported from the United Kingdom, South Africa and Brazil.
Addressing a world webinar “Kerala Health: Making the SDG A Reality,” organised by the Department of Health and Family Welfare, Government of Kerala, Dr Balram Bhargava, Director General of ICMR stated a paper on Covaxin’s neutralisation potential against the UK pressure has been accepted for publication.
In the case of the variants from South Africa and Brazil, efforts have been on to isolate the mutated virus strains from the samples collected from travellers from these two nations, he stated.
The third medical trial of Covaxin BB152 had been accomplished as all of the 25,800 volunteers concerned within the train had been administered each doses. “The interim analysis report should be out in a week.”
Dr Bhargava identified that India was the fifth nation on the earth to isolate the COVID-19 virus as a part of the efforts to develop a vaccine for the pandemic.
“India had from the outset resisted the temptation of going for herd immunity unlike many European countries, including the UK and Italy, and its decision had been vindicated from what happened in the western nations that allowed the pandemic to spread,” he stated.